Author: admin

Migraine Market Forecasted to Surge in Coming Years, 2023-2032 Analysis by DelveInsight | Amgen, Teva Pharma, Eli Lilly, Teva Pharma, Axsome Therapeutics, AEON Biopharma, Charleston Laboratories

The Key Migraine Companies in the market include – Eli Lilly and Company, Teva Pharmaceuticals, Axsome Therapeutics, AEON Biopharma, Inc., Charleston Laboratories, Amgen, Teva Pharmaceuticals, Eli Lilly and Company, Anne Lindblad, Allergan, AbbVie, Tian Medical Inc., Allergan, H. Lundbeck A/S, Tonix Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and others.

 

The Migraine market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Migraine pipeline products will significantly revolutionize the Migraine market dynamics.  

DelveInsight’s “Migraine Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Migraine, historical and forecasted epidemiology as well as the Migraine market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Migraine market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Migraine Market Forecast

 

Some of the key facts of the Migraine Market Report: 

  • The Migraine market size was valued ~USD 10.8 billion in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

  • In September 2024, Click Therapeutics, Inc. (“Click”), a pioneer in Digital Therapeutics™ as prescription medical solutions, announced that its pivotal randomized, double-blind, controlled, decentralized study of CT-132 for migraine prevention, ReMMi-D (Reduction in Monthly Migraine Days, NCT05853900), successfully met its primary endpoint.

  • In 2023, the US had the largest market size for Migraine among the 7MM, totaling approximately USD 6,790 million. This figure is projected to rise further by 2034.

  • In 2023, the market size for episodic migraine (comprising preventive and acute treatments) in the US was approximately USD 4,026 million, while for chronic migraine (including preventive and acute treatments), it was nearly USD 2,766 million in the same year.

  • In 2023, the highest patient share of Migraine in the 7MM was observed in the US, comprising 39% of the total cases, followed by Japan with approximately 14%. In European nations, the UK reported a higher number of cases, representing about 11% of the total 7MM cases.

  • In 2023, the estimated prevalent population of Migraine in the 7MM was approximately 119,233 cases.

  • The total prevalent cases of Migraine in the US are projected to see a notable Compound Annual Growth Rate (CAGR) by 2034, rising from approximately 46,140 cases in 2023.

  • In 2023, Germany reported the highest prevalent population of Migraine among European countries, accounting for 22%, followed by Italy. Conversely, Spain had the lowest prevalent population of Migraine, representing around 17% in the same year.

  • In Japan, the majority of prevalent Migraine cases in 2023 were categorized as Episodic Migraine, totaling approximately 16,331 cases. Conversely, the least prevalent cases were classified as Chronic Migraine, numbering around 950 cases in the same year.

  • According to analyses by DelveInsight’s experts, the majority of Migraine cases are observed in females compared to males. In 2023, there were approximately 11,535 thousand male cases and around 34,605 thousand female cases of Migraine in the US.

  • In the EU4 and the UK, the majority of diagnosed cases of Migraine in 2023 were categorized as Episodic Migraine, totaling approximately 15,839 thousand cases. Conversely, the least diagnosed cases were identified as Chronic Migraine, numbering around 2,411 thousand in the same year.

  • Key Migraine Companies: Eli Lilly and Company, Teva Pharmaceuticals, Axsome Therapeutics, AEON Biopharma, Inc., Charleston Laboratories, Amgen, Teva Pharmaceuticals, Eli Lilly and Company, Anne Lindblad, Allergan, AbbVie, Tian Medical Inc., Allergan, H. Lundbeck A/S, Tonix Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and others

  • Key Migraine Therapies: EMGALITY (Galcanezumab-gnlm), AJOVY (fremanezumab-vfrm), AXS-07, ABP-450, Aimovig, CL-H1T, AIMOVIG, Fremanezumab, propranolol LA, LBR-101, Atogepant, Galcanezumab, Marcaine, Atogepant, Galcanezumab, Eptinezumab, TNX-1900, IONIS-PKKRx (ISIS 546254), and others

  • The Migraine epidemiology based on gender analyzed that females experience a more significant impact in relation to Migraine compared to males

  • The Migraine market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Migraine pipeline products will significantly revolutionize the Migraine market dynamics.

 

Migraine Overview

Migraine is a neurological condition characterized by intense, debilitating headaches often accompanied by other symptoms. Migraines can significantly affect a person’s quality of life, with varying frequency and severity from person to person.

 

Get a Free sample for the Migraine Market Report 

https://www.delveinsight.com/report-store/migraine-market

 

Migraine Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Migraine Epidemiology Segmentation:

The Migraine market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Migraine

  • Prevalent Cases of Migraine by severity

  • Gender-specific Prevalence of Migraine

  • Diagnosed Cases of Episodic and Chronic Migraine

 

Download the report to understand which factors are driving Migraine epidemiology trends @ Migraine Epidemiology Forecast

 

Migraine Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Migraine market or expected to get launched during the study period. The analysis covers Migraine market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Migraine Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Migraine Therapies and Key Companies

  • EMGALITY (Galcanezumab-gnlm): Eli Lilly and Company

  • AJOVY (fremanezumab-vfrm): Teva Pharmaceuticals

  • AXS-07: Axsome Therapeutics

  • ABP-450: AEON Biopharma, Inc.

  • Aimovig: Amgen

  • CL-H1T: Charleston Laboratories

  • AIMOVIG: Amgen

  • Fremanezumab: Teva Pharmaceuticals

  • Galcanezumab: Eli Lilly and Company

  • propranolol LA: Anne Lindblad

  • Atogepant: Allergan

  • LBR-101: Teva Branded Pharmaceutical

  • Atogepant: AbbVie

  • Galcanezumab: Eli Lilly and Company

  • Marcaine: Tian Medical Inc.

  • Atogepant: Allergan

  • Galcanezumab: Eli Lilly and Company

  • Eptinezumab: H. Lundbeck A/S

  • TNX-1900: Tonix Pharmaceuticals, Inc.

  • IONIS-PKKRx (ISIS 546254): Ionis Pharmaceuticals, Inc.

 

Discover more about therapies set to grab major Migraine market share @ Migraine Treatment Market

 

Scope of the Migraine Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Migraine Companies: Eli Lilly and Company, Teva Pharmaceuticals, Axsome Therapeutics, AEON Biopharma, Inc., Charleston Laboratories, Amgen, Teva Pharma, Eli Lilly and Company, Anne Lindblad, Allergan, AbbVie, Tian Medical Inc., Allergan, H. Lundbeck A/S, Tonix Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and others

  • Key Migraine Therapies: EMGALITY (Galcanezumab-gnlm), AJOVY (fremanezumab-vfrm), XS-07, ABP-450, Aimovig, CL-H1T, AIMOVIG, Fremanezumab, propranolol LA, LBR-101, Atogepant, Galcanezumab, Marcaine, Atogepant, Galcanezumab, Eptinezumab, TNX-1900, IONIS-PKKRx (ISIS 546254), and others

  • Migraine Therapeutic Assessment: Migraine current marketed and Migraine emerging therapies

  • Migraine Market Dynamics: Migraine market drivers and Migraine market barriers 

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Migraine Unmet Needs, KOL’s views, Analyst’s views, Migraine Market Access and Reimbursement 

 

To know more about Migraine companies working in the treatment market, visit @ Migraine Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Migraine Market Report Introduction

2. Executive Summary for Migraine

3. SWOT analysis of Migraine

4. Migraine Patient Share (%) Overview at a Glance

5. Migraine Market Overview at a Glance

6. Migraine Disease Background and Overview

7. Migraine Epidemiology and Patient Population

8. Country-Specific Patient Population of Migraine 

9. Migraine Current Treatment and Medical Practices

10. Migraine Unmet Needs

11. Migraine Emerging Therapies

12. Migraine Market Outlook

13. Country-Wise Migraine Market Analysis (2020–2034)

14. Migraine Market Access and Reimbursement of Therapies

15. Migraine Market Drivers

16. Migraine Market Barriers

17.  Migraine Appendix

18. Migraine Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Migraine Market Forecasted to Surge in Coming Years, 2023-2032 Analysis by DelveInsight | Amgen, Teva Pharma, Eli Lilly, Teva Pharma, Axsome Therapeutics, AEON Biopharma, Charleston Laboratories

Microscopic Polyangiitis Market Growth to Accelerate in Forecast Period (2023-2032), DelveInsight Analyzes | Novartis, Genentech, Vifor Pharma, InflaRx GmbH, GlaxoSmithKline, InflaRx GmbH, Roche

Key Microscopic Polyangiitis Companies in the market include – Genentech, Vifor Pharma, InflaRx GmbH, GlaxoSmithKline, InflaRx GmbH, Hoffmann-La Roche, Novartis, and others.

DelveInsight’s “Microscopic Polyangiitis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Microscopic Polyangiitis, historical and forecasted epidemiology as well as the Microscopic Polyangiitis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

The latest healthcare forecast report provides an in-depth analysis of Microscopic Polyangiitis, offering comprehensive insights into the Microscopic Polyangiitis revenue trends, prevalence, and treatment landscape. The report delves into key Microscopic Polyangiitis statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Microscopic Polyangiitis therapies. Additionally, we cover the landscape of Microscopic Polyangiitis clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Microscopic Polyangiitis treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Microscopic Polyangiitis space.

 

To Know in detail about the Microscopic Polyangiitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Microscopic Polyangiitis Market Forecast

 

Some of the key facts of the Microscopic Polyangiitis Market Report: 

  • The Microscopic Polyangiitis market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

  • In 2023, the market size for microscopic polyangiitis across the 7MM was estimated to exceed USD 30 million.

  • Key Microscopic Polyangiitis Companies: Genentech, Vifor Pharma, InflaRx GmbH, GlaxoSmithKline, InflaRx GmbH, Hoffmann-La Roche, Novartis, and others

  • Key Microscopic Polyangiitis Therapies: RITUXAN, TAVNEOS, Vilobelimab (IFX-1, CaCP290), Belimumab, IFX-1, Methylprednisolone, Iptacopan, and others

  • The Microscopic Polyangiitis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Microscopic Polyangiitis pipeline products will significantly revolutionize the Microscopic Polyangiitis market dynamics.

  • In 2023, there were approximately 5,000 incident cases of microscopic polyangiitis across the seven major markets. This number is anticipated to decline during the forecast period, primarily due to population decreases in major contributing countries like Japan and Germany, which are expected to lead to a reduction in incidence rates.

  • In the US, males account for the majority of gender-specific incident cases.

  • Age-specific data indicates that the highest incidence of microscopic polyangiitis occurs in individuals aged 18 years and older, while those aged 0–17 years are the least affected in the US.

 

Microscopic Polyangiitis Overview

Microscopic Polyangiitis (MPA) is a rare autoimmune disease characterized by inflammation of small blood vessels (vasculitis). This condition can affect multiple organs, most commonly the kidneys, lungs, skin, and nervous system. It is associated with the production of antineutrophil cytoplasmic antibodies (ANCAs), which play a role in the immune system’s attack on blood vessels.

 

Get a Free sample for the Microscopic Polyangiitis Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/microscopic-polyangiitis-mpa-market

 

Microscopic Polyangiitis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Microscopic Polyangiitis Epidemiology Segmentation:

The Microscopic Polyangiitis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Microscopic Polyangiitis

  • Prevalent Cases of Microscopic Polyangiitis by severity

  • Gender-specific Prevalence of Microscopic Polyangiitis

  • Diagnosed Cases of Episodic and Chronic Microscopic Polyangiitis

 

Download the report to understand which factors are driving Microscopic Polyangiitis epidemiology trends @ Microscopic Polyangiitis Epidemiology Forecast

 

Microscopic Polyangiitis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Microscopic Polyangiitis market or expected to get launched during the study period. The analysis covers Microscopic Polyangiitis market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Microscopic Polyangiitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Microscopic Polyangiitis Therapies and Key Companies

  • RITUXAN: Genentech

  • TAVNEOS: Vifor Pharma

  • Vilobelimab (IFX-1, CaCP290): InflaRx GmbH

  • Belimumab: GlaxoSmithKline

  • IFX-1: InflaRx GmbH

  • Methylprednisolone: Hoffmann-La Roche

  • Iptacopan: Novartis

 

Discover more about therapies set to grab major Microscopic Polyangiitis market share @ Microscopic Polyangiitis Treatment Landscape

 

Microscopic Polyangiitis Market Drivers

  • Advances in Diagnostic Techniques

  • Rising Awareness

  • Pipeline Therapies

  • Increased Healthcare Access

  • Growing Research Efforts

 

Microscopic Polyangiitis Market Barriers

  • Limited Awareness in Low-Income Regions

  • High Treatment Costs

  • Side Effects of Therapies

  • Rarity of Disease

  • Regulatory Challenges

 

Scope of the Microscopic Polyangiitis Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Microscopic Polyangiitis Companies: Genentech, Vifor Pharma, InflaRx GmbH, GlaxoSmithKline, InflaRx GmbH, Hoffmann-La Roche, Novartis, and others

  • Key Microscopic Polyangiitis Therapies: RITUXAN, TAVNEOS, Vilobelimab (IFX-1, CaCP290), Belimumab, IFX-1, Methylprednisolone, Iptacopan, and others

  • Microscopic Polyangiitis Therapeutic Assessment: Microscopic Polyangiitis current marketed and Microscopic Polyangiitis emerging therapies

  • Microscopic Polyangiitis Market Dynamics: Microscopic Polyangiitis market drivers and Microscopic Polyangiitis market barriers 

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Microscopic Polyangiitis Unmet Needs, KOL’s views, Analyst’s views, Microscopic Polyangiitis Market Access and Reimbursement 

 

To know more about Microscopic Polyangiitis companies working in the treatment market, visit @ Microscopic Polyangiitis Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Microscopic Polyangiitis Market Report Introduction

2. Executive Summary for Microscopic Polyangiitis

3. SWOT analysis of Microscopic Polyangiitis

4. Microscopic Polyangiitis Patient Share (%) Overview at a Glance

5. Microscopic Polyangiitis Market Overview at a Glance

6. Microscopic Polyangiitis Disease Background and Overview

7. Microscopic Polyangiitis Epidemiology and Patient Population

8. Country-Specific Patient Population of Microscopic Polyangiitis 

9. Microscopic Polyangiitis Current Treatment and Medical Practices

10. Microscopic Polyangiitis Unmet Needs

11. Microscopic Polyangiitis Emerging Therapies

12. Microscopic Polyangiitis Market Outlook

13. Country-Wise Microscopic Polyangiitis Market Analysis (2020–2034)

14. Microscopic Polyangiitis Market Access and Reimbursement of Therapies

15. Microscopic Polyangiitis Market Drivers

16. Microscopic Polyangiitis Market Barriers

17.  Microscopic Polyangiitis Appendix

18. Microscopic Polyangiitis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Microscopic Polyangiitis Market Growth to Accelerate in Forecast Period (2023-2032), DelveInsight Analyzes | Novartis, Genentech, Vifor Pharma, InflaRx GmbH, GlaxoSmithKline, InflaRx GmbH, Roche

FEAR-Xane Volume 1: A Groundbreaking Young Adult Novella by Mark White

YA Novella Exploring the Complexities of Human Emotion and Identity in a Futuristic World

The debut installment of The Xane Novellas delves into the intricate spectrum of human emotions, exploring the dynamics of relationships and confronting the most daunting challenge of all—facing one’s deepest fears.

A Tale of Emotion and Identity

In FEAR – Xane Volume 1, author White unveils a groundbreaking narrative that merges futuristic innovation with raw human emotion. Set in the year 2040, the story introduces Xane, a secret Synthetic Human created to experience and understand the full range of human feelings. When a human boy unknowingly falls in love with her, Xane is thrust into the complexity of love and the chaos of teenage relationships. Against the backdrop of a suburban high school—where emotions run high—Xane embarks on a profound journey to investigate and confront fear, one of humanity’s most primal emotions. Through a tapestry of friendship, love, and self-discovery, the story asks a provocative question: can an emotionally intelligent Synth truly coexist with humanity?

Key Themes and Insights

• Facing Fear: This book explores how fear shapes behavior and relationships, offering key strategies for managing it: recognize and name your fear, confront it with small, deliberate steps, seek support from trusted friends or mentors, and reframe fear as an opportunity for growth. Through these approaches, readers learn that fear, though pervasive, can be understood and overcome.

• Confronting Bullying: Inspired by the challenges teens face in navigating high school drama, FEAR – Xane Volume 1 addresses the multifaceted issue of bullying. Through the characters’ journeys of struggle and triumph, the story aims to empower readers, offering them tools to build resilience and face their own challenges with confidence.

• Human and Synthetic Connections: As a Synth with advanced emotional intelligence, Xane demonstrates deep compassion and empathy, forging friendships that explore identity, belonging, and the essence of humanity.

• Young Adult Struggles: Whether it be first loves or fears of social interaction, the author, White, conveys the real come and go of adolescent existence indelibly and convincingly. The reader experiences the emotions and overcomes the struggles that come with them learning true techniques that could be used in real life circumstances.

A Visionary Perspective on Storytelling

Mark C. White masterfully blends captivating themes with compelling narration in his latest venture, The Xane Emotion Series. A fresh voice in young adult storytelling, White crafts novellas that transcend age, offering a thought-provoking journey for readers of all backgrounds. With dynamic characters, engaging dialogue, and a powerful exploration of artificial intelligence, the series seamlessly bridges today’s technological advancements with timeless human emotions, making it both relatable and deeply stimulating.

He states, “This narrative is not only limited to a narration of the expansive world that Xane exists in it’s wider than that.” “It’s about the fears we suppress, the relationships we crave, and the risk of intimacy. Through Xane, I wanted to show that fear is not meant to be conquered; it is meant to be acknowledged, understood, and embraced.”

Behind the Inspiration

Author Mark C. White infuses The Xane Emotion Series with a deep passion for understanding human emotions, seamlessly integrating psychological insights into an engaging sci-fi narrative. By combining proven emotional management techniques with futuristic storytelling, White transforms complex concepts into a compelling and memorable tale. Drawing from his personal experiences and studies of human interaction, he introduces Xane—a character who redefines our understanding of fear, love, and identity. This thought-provoking series celebrates humanity’s resilience and the universal drive to connect, even in the most extraordinary situations.

Praise for FEAR – Xane Volume 1

White has been commended by both critics and early audiences for Mark’s skill in fusing emotional elements with an easy-to-read, gripping narrative.

One reader said’ this book is an excellent study about being a human, the study has even been interrogated by a nonhuman.’ Another pointed out, “Mark C. White’s storytelling is not only uplifting, but it can also be quite comforting because it reminds one that the most intense nightmares are those that hold the greatest truths about even oneself.”

About the Author

Mark C. White is an author with extraordinary creative talent, vividly showcased in the pages of FEAR – Xane Volume 1. After writing Fear, White expanded the series to explore the six primary emotions, five secondary emotions, and the deeply intricate emotion of love. His dedication to examining the relationship between humans and machines, coupled with a focus on empowering readers to face their fears, makes his work both compelling and relatable.

Availability and Contact Information

Xane: Volume 1 of the FEAR Series is available for both print and digital. For questions, interviews, and review copies, please use the contacts below.

Media Contact
Company Name: The Empire Publishers (USA)
Contact Person: Mark C. White
Email: Send Email
City: Arlington
State: Texas
Country: United States
Website: https://www.theempirepublishers.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: FEAR-Xane Volume 1: A Groundbreaking Young Adult Novella by Mark White

A Whimsical Adventure: Pepper the Chicken Explores Niagara Falls

A New Children’s Book by Henry B. Neufeld Takes Readers on a Fun-Filled Journey

Author Henry B. Neufeld is excited to introduce his latest children’s book, Adventures with Pepper: Pepper Goes to Niagara Falls.

This beautiful, adventurous story takes kids on a fun trip to the wonderful Niagara Falls with Pepper the Chicken. Through a series of exciting events, I invite young readers to enjoy the sights and sounds of this natural wonder in a more vivid way.

A Fun and Educational Adventure for Kids

In Adventures with Pepper: Pepper Goes to Niagara Falls, the character of Pepper is amazing, and it has the spark to become children’s favorite character in no time. Pepper goes on an exciting exploratory and discovery-oriented trip. On a visit to Niagara Falls, there are quite a number of activities on Pepper’s schedule that will, without doubt, excite the fantasies of the children. Whether it is riding in an exciting helicopter, going to an aviary and zip lining, or any of the many other activities in between, Pepper’s exploits are filled with new activities that will provoke the imagination of little children.

Key Moments in Pepper’s Adventure Include

• A Close-Up View of Niagara Falls: Watch Pepper as she enjoys a strong waterfall and takes in the mist on her feathers.

• Flying High: Feel the thrill of taking a helicopter ride above Niagara Falls with Pepper.

• Birdwatching at the Aviary: Kids meet different birds from around the world when Pepper – a clever yet cute bird – becomes a guide.

• A Day at the Butterfly Conservatory: Brightly colored butterflies hover around Pepper, teaching kids the beauty and variety of nature.

This narrative has fun-filled adventures that are meant to help extinguish the curiosity of the children.

The Heart Behind the Story

Henry B. Neufeld is a born writer whose sole aspiration was to prod the kids in the spirit of adventure and exploration. He was born in Mexico but later moved to Canada. That is why, in all his works, Neufeld has always included elements of narrative. Adventures with Pepper was born in Neufeld’s mind as a means of incorporating elements of fun and play into children and motivating them to explore their surroundings.

“Adventures with Pepper is geared towards children in a manner which makes it necessary for them to think, move about, and appreciate what is beyond their imagination,” Neufeld says. “Niagara Falls is such a beautiful place, filled with breathtaking sights and sounds, and I wanted to give a taste of that to my young readers through the character of Pepper.

Vibrant Illustrations that Bring Pepper to Life

What makes Adventures with Pepper exceptional are its beautiful visuals that go along with the fun storytelling. The vivid visuals of the book capture each of Peppe’s escapades and gives children a visual perspective of the story. Whether it’s the sweeping sights of Niagara Falls or the miniature butterflies in the greenhouse, the pictures appeal to children’s imaginations and whisk them away to an adventure, making it feel as though they are with Pepper.

Perfect for Children and Educators

For kids aged three to eight years, Adventures with Pepper is an excellent book for parents who want to start their children on the journey of the natural world and exploration.

This attractive story that nurtures the child’s curiosity also contributes towards a positive attitude towards environmental awareness, and a love of exploration.

About the Author

Henry B. Neufeld is a debut author of children’s books who moved to Canada from Mexico when he was nine years old and discovered his love for telling stories. Using her experiences and her passion, Neufeld founded Adventures with Pepper to show children how fun and thrilling it is to explore the world.

When not writing, Neufeld loves to relax with family, travel, and visit new places. Adventures with Pepper, although his debut book, is the first book that brings about the author’s ambitions to life. Get ready to explore the enchanting Niagara Falls and the fun adventure of Pepper the Chicken. Place a pre-order for Adventures with Pepper: Pepper Goes to Niagara Falls right now!

Praise for Adventures with Pepper

Neufeld’s enchanting storytelling, together with the illustrations in the book, has won the hearts of early readers.

“My kids absolutely loved Adventures with Pepper! The story is so exciting, and the illustrations are really vibrant and delicious. It was a brilliant way of making them talk about their own adventures.” – Jennifer P., Parent.

“My students were mesmerized by Pepper. They enjoyed the adventures Pepper had with them at Niagara Falls, and it led to great conversations.” – Karen W., Teacher.

Availability

Adventures with Pepper: Pepper Goes to Niagara Falls can be bought from a number of retail stores, as well as in several eBook stores. This book is just right for young adventurers and would make an excellent vacation gift for inquisitive children.

Media Contact
Company Name: The Empire Publishers
Contact Person: Henry Neufeld
Email: Send Email
Country: Canada
Website: https://www.theempirepublishers.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: A Whimsical Adventure: Pepper the Chicken Explores Niagara Falls

Metastatic Prostate Cancer Market to Show Remarkable Growth Trends from 2023 to 2032, DelveInsight Reports | Merck, Arvinas Androgen Receptor, Novartis, UNICANCER, Aragon Pharma, Mark Stein

The Key Metastatic Prostate Cancer Companies in the market include – Curium US LLC, Bayer, Hookipa Biotech GmbH, University Health Network, Merck Sharp & Dohme, Arvinas Androgen Receptor, UNICANCER, Aragon Pharmaceuticals, Mark Stein, Novartis, Orion Corporation, Janssen Research & Development, AstraZeneca, MedSIR, Aragon Pharmaceuticals, and others.

 

DelveInsight’s “Metastatic Prostate Cancer Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Metastatic Prostate Cancer, historical and forecasted epidemiology as well as the Metastatic Prostate Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Metastatic Prostate Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Metastatic Prostate Cancer Market Forecast

 

Some of the key facts of the Metastatic Prostate Cancer Market Report: 

  • The Metastatic Prostate Cancer market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

  • In September 2024, Ipsen reported that the Phase III CONTACT-02 trial evaluating Cabometyx in combination with atezolizumab for mCRPC demonstrated a non-significant improvement in overall survival but successfully met the progression-free survival (PFS) endpoint.

  • In August 2024, Nuvation Bio announced that the US Food and Drug Administration has approved its investigational new drug application to study NUV-1511, the first clinical candidate developed from the company’s innovative drug-drug conjugate (DDC) platform.

  • In July 2024, The FDA has awarded fast-track designation to SYNC-T SV-102 for the treatment of metastatic castration-resistant prostate cancer (mCRPC).

  • In June 2024, Kangpu Biopharmaceuticals secured FDA approval to conduct a Phase II/III trial of KPG-121 in combination with Abiraterone for metastatic castration-resistant prostate cancer (mCRPC).

  • In June 2024, BioNTech SE and Duality Biologics announced that the US Food and Drug Administration has granted Fast Track designation to BNT324/DB-1311 for the treatment of patients with advanced, unresectable, or metastatic castration-resistant prostate cancer (CRPC) who have progressed following standard systemic treatments.

  • In May 2024, Fusion Pharmaceuticals launched the Phase II AlphaBreak trial of FPI-2265 in patients with metastatic castration-resistant prostate cancer (mCRPC).

  • According to DelveInsight estimates, the total prevalent population of prostate cancer in the seven major markets (7MM) was approximately 8,241,400 cases in 2023. This number is expected to rise over the study period.

  • In 2023, the United States had the highest number of diagnosed prostate cancer cases, with approximately 1,506,200 reported cases.

  • In the US, the total diagnosed prevalent cases of prostate cancer by clinical stages were highest in locally advanced stages (Stage I–III), with over 903,700 cases in 2023, followed by biochemical recurrence/progressive and metastatic cases, respectively.

  • Key Metastatic Prostate Cancer Companies: Curium US LLC, Bayer, Hookipa Biotech GmbH, University Health Network, Merck Sharp & Dohme, Arvinas Androgen Receptor, UNICANCER, Aragon Pharmaceuticals, Mark Stein, Novartis, Orion Corporation, Janssen Research & Development, AstraZeneca, MedSIR, Aragon Pharmaceuticals, Janssen Research & Development, Telix Pharmaceuticals, Alliance Foundation Trials, Epizyme, Inc., Exelixis, and others

  • Key Metastatic Prostate Cancer Therapies: 177Lu-PSMA-I&T, Darolutamide (Nubeqa, BAY1841788), HB-302/HB-301, Enzalutamide, Opevesostat, Pembrolizumab, ARV-766 Part A&B, Darolutamide, Apalutamide, REGN2810, 177Lu-PSMA-617, ODM-208, Apalutamide, AZD0754, Enzalutamide, Apalutamide, Niraparib, 177Lu-DOTA-rosopatamb, Darolutamide, Tazemetostat, Cabozantinib, and others

  • The Metastatic Prostate Cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Metastatic Prostate Cancer pipeline products will significantly revolutionize the Metastatic Prostate Cancer market dynamics.

 

Metastatic Prostate Cancer Overview

Metastatic prostate cancer is an advanced form of prostate cancer that has spread beyond the prostate gland to other parts of the body. This stage of prostate cancer, also known as stage IV, is characterized by the cancer’s ability to metastasize, meaning it travels through the bloodstream or lymphatic system to form new tumors in distant organs and tissues.

 

Get a Free sample for the Metastatic Prostate Cancer Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/metastatic-prostate-cancer-market

 

Metastatic Prostate Cancer Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Metastatic Prostate Cancer Epidemiology Segmentation:

The Metastatic Prostate Cancer market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Metastatic Prostate Cancer

  • Prevalent Cases of Metastatic Prostate Cancer by severity

  • Gender-specific Prevalence of Metastatic Prostate Cancer

  • Diagnosed Cases of Episodic and Chronic Metastatic Prostate Cancer

 

Download the report to understand which factors are driving Metastatic Prostate Cancer epidemiology trends @ Metastatic Prostate Cancer Epidemiology Forecast

 

Metastatic Prostate Cancer Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Metastatic Prostate Cancer market or expected to get launched during the study period. The analysis covers Metastatic Prostate Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Metastatic Prostate Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Metastatic Prostate Cancer Therapies and Key Companies

  • 177Lu-PSMA-I&T: Curium US LLC

  • Darolutamide (Nubeqa, BAY1841788): Bayer

  • HB-302/HB-301: Hookipa Biotech GmbH

  • Enzalutamide: University Health Network

  • Opevesostat: Merck Sharp & Dohme

  • Pembrolizumab: Merck Sharp & Dohme

  • ARV-766 Part A&B: Arvinas Androgen Receptor

  • Darolutamide: UNICANCER

  • Apalutamide: Aragon Pharmaceuticals

  • REGN2810: Mark Stein

  • 177Lu-PSMA-617: Novartis

  • ODM-208: Orion Corporation, Orion Pharma

  • Apalutamide: Janssen Research & Development

  • AZD0754: AstraZeneca

  • Enzalutamide: MedSIR

  • Apalutamide: Aragon Pharmaceuticals

  • Niraparib: Janssen Research & Development

  • 177Lu-DOTA-rosopatamb: Telix Pharmaceuticals

  • Darolutamide: Alliance Foundation Trials

  • Tazemetostat: Epizyme, Inc.

  • Cabozantinib: Exelixis

 

Discover more about therapies set to grab major Metastatic Prostate Cancer market share @ Metastatic Prostate Cancer Treatment Landscape

 

Metastatic Prostate Cancer Market Strengths

  • The emergence of PASMA-PET imaging have significantly improved the diagnostic landscape of advance prostate cancer.

  • Astella’s XTANDI, which has approval in maximum prostate cancer indications is the highest revenue generator among all approved therapies in prostate cancer. Though XTANDI’s revenue is driven by prescribing volume, an increasing share of the drug’s revenue is driven by price increases in recent years.

 

Metastatic Prostate Cancer Market Opportunities

  • The developmental pipeline for mCSPC is dry compared to that of mCRPC. Thus, the market for mCSPC holds considerable scope for upcoming therapies owing to the availability of only a handful of approved drugs for its patient pool.

  • Although triplet therapy techniques have not yet been fully investigated, analysis shows that patients with de novo metastatic disease and a high-volume disease burden benefited most from this approach.

 

Scope of the Metastatic Prostate Cancer Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Metastatic Prostate Cancer Companies: Curium US LLC, Bayer, Hookipa Biotech GmbH, University Health Network, Merck Sharp & Dohme, Arvinas Androgen Receptor, UNICANCER, Aragon Pharmaceuticals, Mark Stein, Novartis, Orion Corporation, Janssen Research & Development, AstraZeneca, MedSIR, Aragon Pharmaceuticals, Janssen Research & Development, Telix Pharmaceuticals, Alliance Foundation Trials, Epizyme, Inc., Exelixis, and others

  • Key Metastatic Prostate Cancer Therapies: 177Lu-PSMA-I&T, Darolutamide (Nubeqa, BAY1841788), HB-302/HB-301, Enzalutamide, Opevesostat, Pembrolizumab, ARV-766 Part A&B, Darolutamide, Apalutamide, REGN2810, 177Lu-PSMA-617, ODM-208, Apalutamide, AZD0754, Enzalutamide, Apalutamide, Niraparib, 177Lu-DOTA-rosopatamb, Darolutamide, Tazemetostat, Cabozantinib, and others

  • Metastatic Prostate Cancer Therapeutic Assessment: Metastatic Prostate Cancer current marketed and Metastatic Prostate Cancer emerging therapies

  • Metastatic Prostate Cancer Market Dynamics: Metastatic Prostate Cancer market drivers and Metastatic Prostate Cancer market barriers 

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Metastatic Prostate Cancer Unmet Needs, KOL’s views, Analyst’s views, Metastatic Prostate Cancer Market Access and Reimbursement 

 

To know more about Metastatic Prostate Cancer companies working in the treatment market, visit @ Metastatic Prostate Cancer Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Metastatic Prostate Cancer Market Report Introduction

2. Executive Summary for Metastatic Prostate Cancer

3. SWOT analysis of Metastatic Prostate Cancer

4. Metastatic Prostate Cancer Patient Share (%) Overview at a Glance

5. Metastatic Prostate Cancer Market Overview at a Glance

6. Metastatic Prostate Cancer Disease Background and Overview

7. Metastatic Prostate Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of Metastatic Prostate Cancer 

9. Metastatic Prostate Cancer Current Treatment and Medical Practices

10. Metastatic Prostate Cancer Unmet Needs

11. Metastatic Prostate Cancer Emerging Therapies

12. Metastatic Prostate Cancer Market Outlook

13. Country-Wise Metastatic Prostate Cancer Market Analysis (2020–2034)

14. Metastatic Prostate Cancer Market Access and Reimbursement of Therapies

15. Metastatic Prostate Cancer Market Drivers

16. Metastatic Prostate Cancer Market Barriers

17.  Metastatic Prostate Cancer Appendix

18. Metastatic Prostate Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Metastatic Prostate Cancer Market to Show Remarkable Growth Trends from 2023 to 2032, DelveInsight Reports | Merck, Arvinas Androgen Receptor, Novartis, UNICANCER, Aragon Pharma, Mark Stein

Menkes Disease Market Expected to Experience Major Growth by 2034, According to DelveInsight | Cyprium Therapeutics and Sentynl Therapeutics, Cyprium Therapeutics, Inc.

The Key Menkes Disease Companies in the market include – Cyprium Therapeutics and Sentynl Therapeutics, Cyprium Therapeutics, Inc., and others.

 

DelveInsight’s “Menkes Disease Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Menkes Disease, historical and forecasted epidemiology as well as the Menkes Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Menkes Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Menkes Disease Market Forecast

 

Some of the key facts of the Menkes Disease Market Report: 

  • The Menkes Disease market size was valued ~USD 8 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

  • The Standard of Care accounted for the entire market, which was valued at approximately USD 7.9 million in 2023 across the 7MM.

  • According to our assessment, there were approximately 177 diagnosed prevalent cases of Menkes Disease in the 7MM in 2023, with expectations for these numbers to rise by 2034. The US had the highest number of cases.

  • Among European countries in 2023, France had the highest diagnosed prevalent cases of Menkes Disease at 26%, followed by Germany and the UK, each with 24%. Conversely, Spain had the lowest diagnosed prevalence, accounting for 11%.

  • In 2023, the US represented the largest share of diagnosed Menkes disease cases in the 7MM, with 54%, followed by Japan, which accounted for approximately 11%. Among European countries, France had the highest number of cases, representing about 9% of the total 7MM cases.

  • In 2023, France held the largest market share in the EU4 and UK region with 27%, while Spain had the smallest share at 12%.

  • The 7MM treatment market currently lacks an approved targeted therapy for Menkes Disease. However, with the anticipated launch of CUTX-101 by 2025, the market is expected to see significant growth.

  • Key Menkes Disease Companies: Cyprium Therapeutics and Sentynl Therapeutics, Cyprium Therapeutics, Inc., and others

  • Key Menkes Disease Therapies: CUTX-101, Copper Histidinate, and others

  • The Menkes Disease epidemiology based on gender analyzed that Menkes Disease usually affects male neonates through unaffected carrier women. It may occurs in females, related to unusual genetic circumstances

  • The Menkes Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Menkes Disease pipeline products will significantly revolutionize the Menkes Disease market dynamics.

 

Menkes Disease Overview

Menkes disease (MD) is an X-linked inherited fatal infantile neurodegenerative condition. Mutations in the ATP7A gene, which is in charge of carrying copper throughout the body, result in this inherited X-linked recessive illness.

 

Get a Free sample for the Menkes Disease Market Report: 

https://www.delveinsight.com/report-store/menkes-disease-market

 

Menkes Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Menkes Disease Epidemiology Segmentation:

The Menkes Disease market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Menkes Disease

  • Prevalent Cases of Menkes Disease by severity

  • Gender-specific Prevalence of Menkes Disease

  • Diagnosed Cases of Episodic and Chronic Menkes Disease

 

Download the report to understand which factors are driving Menkes Disease epidemiology trends @ Menkes Disease Epidemiology Forecast

 

Menkes Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Menkes Disease market or expected to get launched during the study period. The analysis covers Menkes Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Menkes Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Menkes Disease Therapies and Key Companies

  • Copper Histidinate: Cyprium Therapeutics, Inc.

  • CUTX-101: Cyprium Therapeutics and Sentynl Therapeutics

 

Menkes Disease Market Drivers

  • Submission of NDA of CUTX-101

  • Increasing awareness among families who have a history of Menkes

  • Parents of affected babies understand the rarity of the disease and allow their children to be a part of the trial

  • Ongoing development of screening techniques

  • Ongoing development of gene therapy

 

Menkes Disease Market Barriers

  • Clinical challenges in the early diagnosis of disease

  • Inability to trace the carrier mother

  • Insufficient number of studies to estimate the exact number of Menkes patients

  • Insufficient number of researches for the treatment of Menkes disease

 

Discover more about therapies set to grab major Menkes Disease market share @ Menkes Disease Treatment Market

 

Scope of the Menkes Disease Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Menkes Disease Companies: Cyprium Therapeutics and Sentynl Therapeutics, Cyprium Therapeutics, Inc., and others

  • Key Menkes Disease Therapies: CUTX-101, Copper Histidinate, and others

  • Menkes Disease Therapeutic Assessment: Menkes Disease current marketed and Menkes Disease emerging therapies

  • Menkes Disease Market Dynamics: Menkes Disease market drivers and Menkes Disease market barriers 

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Menkes Disease Unmet Needs, KOL’s views, Analyst’s views, Menkes Disease Market Access and Reimbursement 

 

To know more about Menkes Disease companies working in the treatment market, visit @ Menkes Disease Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Menkes Disease Market Report Introduction

2. Executive Summary for Menkes Disease

3. SWOT analysis of Menkes Disease

4. Menkes Disease Patient Share (%) Overview at a Glance

5. Menkes Disease Market Overview at a Glance

6. Menkes Disease Disease Background and Overview

7. Menkes Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Menkes Disease 

9. Menkes Disease Current Treatment and Medical Practices

10. Menkes Disease Unmet Needs

11. Menkes Disease Emerging Therapies

12. Menkes Disease Market Outlook

13. Country-Wise Menkes Disease Market Analysis (2020–2034)

14. Menkes Disease Market Access and Reimbursement of Therapies

15. Menkes Disease Market Drivers

16. Menkes Disease Market Barriers

17.  Menkes Disease Appendix

18. Menkes Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Menkes Disease Market Expected to Experience Major Growth by 2034, According to DelveInsight | Cyprium Therapeutics and Sentynl Therapeutics, Cyprium Therapeutics, Inc.

Priil Launches Next-Gen Antivirus to Revolutionize Digital Security

“Priil Security for your computer.”
Priil launches its next-generation antivirus solution, offering technologies & features that is beyond traditional antivirus, for individuals and businesses worldwide.

Priil, the leading software company, has announced its incredible next-generation antivirus solution, developed with the intention to safeguard today’s digital life from modern online threats. A European company based in Bulgaria and incorporated in 2020, Priil is driven by a vision to create a safer digital environment for all devices, free from malware, ransomware, viruses, and the latest modern threats that emerge every second. Designed with advanced technologies and features, real-time threat protection, intuitive functionality, and responsive support, Priil ensures not just to offer enhanced privacy but also optimized device performance that is beyond traditional antivirus for a smoother user experience.

In an era where cyber attacks are becoming increasingly sophisticated, Priil experts have introduced more innovative technologies to safeguard your data. Its software has real-time powerful detection capabilities that block, delete, or quarantine threats instantly. By leveraging advanced technologies and behavior analysis, Priil’s next-generation antivirus solution identifies malware not just through their attributes but also by understanding 99% of the behavior and intentions of modern-day threats, thus, neutralizing and preventing them from causing any kind of harm to your system.

“We have a team of experts that bring innovation wrapped in the latest technologies to fight against threats in your online space,” said Priil’s CEO, Dipranjan Jana. “We offer a range of products, including Priil Antivirus and Priil Internet Security, alongside free trials tailored to fit every user’s needs and budget.”

With online activities surging, users are at higher risk of falling victim to cyberattacks. Privacy is being breached, and users’ personal information and data are stolen and misused by malicious entities. Security is the utmost concern and cannot be overlooked. Whether it is a business running its operation online, storing sensitive data, and sharing critical documents, or an individual inadvertently clicking suspicious links and falling into hackers’ traps disguised as legitimate activities, the concern remains the same. The CEO added, “We are here to revolutionize the cybersecurity industry and make a difference by helping and protecting everyone from the evolving modern vulnerabilities with Priil’s next-generation antivirus solution.”

Priil Antivirus’s comprehensive features include browser safety, VPN protection, PC Optimizer, advanced real-time scanning modes, PC booster, file shredder, and everything that makes user online activities, digital footprints, data, and online banking safe and secure. The Priil Antivirus solution and Priil Internet Security solution instantly block all malicious activities offering a peace of mind throughout your online experience.

About Priil

Priil is a software based company incorporated in 2020, committed to safeguarding your digital life with the latest technological solutions to fight against online threats and attacks. Priil delivers a result-oriented, budget-friendly solution that not only satisfies users but also delights them.

To learn more visit: https://priil.com/

Media Contact
Company Name: Priil Ltd.
Contact Person: Ana Dimitrova
Email: Send Email
Country: Bulgaria
Website: https://priil.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Priil Launches Next-Gen Antivirus to Revolutionize Digital Security

Marginal Zone Lymphoma Market Growth to Accelerate in Forecast Period (2023-2032), DelveInsight Analyzes | Gilead Sciences, AstraZeneca, Nordic Nanovector, Christian Buske, AbbVie, Pharmacyclics LLC

The Key Marginal Zone Lymphoma Companies in the market include – Bristol-Myers Squibb, TG Therapeutics, Gilead Sciences, AstraZeneca, Nordic Nanovector, Christian Buske, AbbVie, Pharmacyclics LLC, Hutchison Medipharma, Beigene, Incyte Corporation, Enterome, and others.

 

DelveInsight’s “Marginal Zone Lymphoma Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Marginal Zone Lymphoma, historical and forecasted epidemiology as well as the Marginal Zone Lymphoma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Marginal Zone Lymphoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Marginal Zone Lymphoma Market Forecast

 

Some of the key facts of the Marginal Zone Lymphoma Market Report: 

  • The Marginal Zone Lymphoma market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

  • In August 2024, The UK National Institute for Health and Care Excellence (NICE) has endorsed BeiGene’s Zanubrutinib (Brukinsa) for treating marginal zone lymphoma (MZL), a form of blood cancer, within the National Health Service (NHS). This approval introduces a new treatment option for patients in England, with the potential to slow cancer progression and reduce the need for additional chemotherapy.

  • In 2023, the United States recorded the highest number of marginal zone lymphoma (MZL) incidence cases among the 7MM, exceeding 8,000 cases. This number is projected to grow throughout the forecast period.

  • In gender-specific Marginal Zone Lymphoma incidence cases, males represent the predominant group.

  • In 2023, MALT lymphoma accounted for the largest proportion of incident cases in the US, comprising approximately 70%, followed by SMZL and NMZL.

  • In the US in 2023, stage-specific incidence of Marginal Zone Lymphoma was highest for Stage III-IV cases, followed by Stage I and Stage II.

  • YESCARTA and BREYANZI are gaining recognition as promising treatments for MZL, with BREYANZI anticipated to receive approval for third-line (3L+) MZL cases by 2026.

  • Key Marginal Zone Lymphoma Companies: Bristol-Myers Squibb, TG Therapeutics, Gilead Sciences, AstraZeneca, Nordic Nanovector, Christian Buske, AbbVie, Pharmacyclics LLC, Hutchison Medipharma, Beigene, Incyte Corporation, Enterome, and others

  • Key Marginal Zone Lymphoma Therapies: REVLIMID (lenalidomide), UKONIQ (umbralisib), BREYANZI (lisocabtagene maraleucel), Yescarta, Calquence, Betalutin, Obinutuzumab, Rituximab, Ibrutinib, HMPL-689, Zanubrutinib, tafasitamab, EO2463, and others

  • The Marginal Zone Lymphoma epidemiology based on gender analyzed that a higher number of males were affected by this disease, i.e., ~54%of the total incident MZL population in the United States, which is equivalent to ~4,300 cases. In comparison to this, for females, the number of cases observed was ~3,700 in 2022.

  • The Marginal Zone Lymphoma market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Marginal Zone Lymphoma pipeline products will significantly revolutionize the Marginal Zone Lymphoma market dynamics.

 

Marginal Zone Lymphoma Overview

Marginal Zone Lymphoma (MZL) is a type of non-Hodgkin lymphoma, a cancer that originates in white blood cells called lymphocytes. MZL specifically affects a subset of these lymphocytes known as marginal zone B-cells, which are found at the edges, or margins, of lymphoid tissues like the lymph nodes, spleen, and mucosa-associated lymphoid tissue (MALT) such as the stomach, salivary glands, or other organs.

 

Get a Free sample for the Marginal Zone Lymphoma Market Forecast, Size & Share Analysis Report: 

http://delveinsight.com/report-store/marginal-zone-lymphoma-market

 

Marginal Zone Lymphoma Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Marginal Zone Lymphoma Epidemiology Segmentation:

The Marginal Zone Lymphoma market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Marginal Zone Lymphoma

  • Prevalent Cases of Marginal Zone Lymphoma by severity

  • Gender-specific Prevalence of Marginal Zone Lymphoma

  • Diagnosed Cases of Episodic and Chronic Marginal Zone Lymphoma

 

Download the report to understand which factors are driving Marginal Zone Lymphoma epidemiology trends @ Marginal Zone Lymphoma Epidemiology Forecast

 

Marginal Zone Lymphoma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Marginal Zone Lymphoma market or expected to get launched during the study period. The analysis covers Marginal Zone Lymphoma market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Marginal Zone Lymphoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Marginal Zone Lymphoma Therapies and Key Companies

  • REVLIMID (lenalidomide): Bristol-Myers Squibb

  • UKONIQ (umbralisib): TG Therapeutics

  • BREYANZI (lisocabtagene maraleucel): Bristol Myers Squibb

  • Yescarta: Gilead Sciences

  • Calquence: AstraZeneca

  • Betalutin: Nordic Nanovector

  • Obinutuzumab: Christian Buske

  • Rituximab: AbbVie

  • Ibrutinib: Pharmacyclics LLC

  • HMPL-689: Hutchison Medipharma

  • Zanubrutinib: Beigene

  • tafasitamab: Incyte Corporation

  • EO2463: Enterome

 

Discover more about therapies set to grab major Marginal Zone Lymphoma market share @ Marginal Zone Lymphoma Treatment Landscape

 

Scope of the Marginal Zone Lymphoma Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Marginal Zone Lymphoma Companies: Bristol-Myers Squibb, TG Therapeutics, Gilead Sciences, AstraZeneca, Nordic Nanovector, Christian Buske, AbbVie, Pharmacyclics LLC, Hutchison Medipharma, Beigene, Incyte Corporation, Enterome, and others

  • Key Marginal Zone Lymphoma Therapies: REVLIMID (lenalidomide), UKONIQ (umbralisib), BREYANZI (lisocabtagene maraleucel), Yescarta, Calquence, Betalutin, Obinutuzumab, Rituximab, Ibrutinib, HMPL-689, Zanubrutinib, tafasitamab, EO2463, and others

  • Marginal Zone Lymphoma Therapeutic Assessment: Marginal Zone Lymphoma current marketed and Marginal Zone Lymphoma emerging therapies

  • Marginal Zone Lymphoma Market Dynamics: Marginal Zone Lymphoma market drivers and Marginal Zone Lymphoma market barriers 

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Marginal Zone Lymphoma Unmet Needs, KOL’s views, Analyst’s views, Marginal Zone Lymphoma Market Access and Reimbursement 

 

To know more about Marginal Zone Lymphoma companies working in the treatment market, visit @ Marginal Zone Lymphoma Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Marginal Zone Lymphoma Market Report Introduction

2. Executive Summary for Marginal Zone Lymphoma

3. SWOT analysis of Marginal Zone Lymphoma

4. Marginal Zone Lymphoma Patient Share (%) Overview at a Glance

5. Marginal Zone Lymphoma Market Overview at a Glance

6. Marginal Zone Lymphoma Disease Background and Overview

7. Marginal Zone Lymphoma Epidemiology and Patient Population

8. Country-Specific Patient Population of Marginal Zone Lymphoma 

9. Marginal Zone Lymphoma Current Treatment and Medical Practices

10. Marginal Zone Lymphoma Unmet Needs

11. Marginal Zone Lymphoma Emerging Therapies

12. Marginal Zone Lymphoma Market Outlook

13. Country-Wise Marginal Zone Lymphoma Market Analysis (2020–2034)

14. Marginal Zone Lymphoma Market Access and Reimbursement of Therapies

15. Marginal Zone Lymphoma Market Drivers

16. Marginal Zone Lymphoma Market Barriers

17.  Marginal Zone Lymphoma Appendix

18. Marginal Zone Lymphoma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Marginal Zone Lymphoma Market Growth to Accelerate in Forecast Period (2023-2032), DelveInsight Analyzes | Gilead Sciences, AstraZeneca, Nordic Nanovector, Christian Buske, AbbVie, Pharmacyclics LLC

Lumenalta’s Agile Model Delivers Results Faster Than Traditional Consulting

Lumenalta, a trailblazer in digital consulting, has redefined agile project delivery with the introduction of its “ship weekly” model, providing clients with real-time engagement in every phase of product development. This innovative approach, which blends rapid iteration with hands-on client involvement, is crafted to help companies in time-sensitive industries stay competitive, adaptive, and fully aligned with evolving market demands.

Lumenalta’s “ship weekly” model allows clients to experience their technology solutions taking shape week by week, rather than waiting for traditional milestone-based delivery cycles. Each week, clients meet with senior developers, product analysts, and designers, gaining visibility into every stage of development. This regular cadence of collaborative demos and feedback ensures the technology solutions align closely with business objectives from inception through delivery.

Delivering speed to value and unmatched client control

In an environment where speed is essential, Lumenalta’s agile model goes beyond delivery — it enhances value by keeping clients actively involved in the process. The “ship weekly” approach enables businesses to see, test, and refine their solutions as they develop, providing a degree of control often missing from standard consulting models.

“With our ‘ship weekly’ model, we’re breaking down the traditional barriers between consulting firms and clients,” states Kuty Shalev, CEO of Lumenalta. “Instead of waiting months to see results, our clients are embedded in the process from day one, shaping solutions in real time. This isn’t just agile delivery; it’s radical engagement.”

A transformative solution for high-stakes industries

Industries such as finance, logistics, and retail, where digital transformation is both a strategic priority and a competitive necessity, benefit significantly from Lumenalta’s model. By participating in regular feedback sessions, clients are not only able to adapt their solutions to changing needs but can also rapidly scale initiatives without costly delays or misalignments.

For instance, in retail, where customer experience must continuously evolve, Lumenalta’s model allows companies to integrate new customer-facing features weekly, ensuring swift adjustments based on real-time consumer insights. In logistics, where operations must adapt to dynamic demand and supply chain shifts, Lumenalta’s model enables operational leaders to tailor technological enhancements with unparalleled agility, keeping them one step ahead.

Lumenalta’s advantage: speed, expertise, and radical engagement

Lumenalta’s agile approach prioritizes rapid delivery without compromising quality, creating a unique advantage for clients. The company’s process is structured around three distinct phases—phase 0 (background and prototype testing), phase I (lean startup methodology), and phase II (agile development). This phased approach enables Lumenalta to deliver solutions in weeks rather than months, evolving each project with client needs at the forefront.

Throughout this process, clients work closely with senior engineers who are not only highly skilled but deeply committed to each project. With more than 90% team retention, Lumenalta’s engineers bring stability and dedication to every engagement. Clients benefit from an experienced team that values experimentation, rapid iteration, and proactive problem-solving, creating an environment where innovation thrives.

“By nurturing a culture of empowerment and collaboration, we enable our people to create better, more innovative technology and deliver superior outcomes and an improved experience for our clients,” also states Shalev.

Unlike traditional consultancies, Lumenalta’s model removes low-value, time-consuming tasks in favor of frequent demos, collaborative feedback sessions, and continuous product refinement. Clients are empowered to have a voice at every stage, enabling them to co-create and shape solutions in real-time without the delays and rigid structures typical of other firms.

Driving ROI and strategic value through agile engagementBy embracing rapid, iterative development, Lumenalta helps clients capture ROI sooner and ensures solutions remain aligned with their strategic priorities. Each weekly demo provides a forum for decision-makers to steer the direction of the project, facilitating faster pivots and reducing the risk of costly rework down the line.

This combination of speed, agility, and deep collaboration translates into a unique competitive edge for Lumenalta’s clients. With the ability to adapt quickly, businesses are equipped to turn insights into action and maintain a leading position in their markets. This flexible approach also allows Lumenalta to anticipate client needs, incorporating emerging technologies such as AI and machine learning to deliver future-proof solutions.

About Lumenalta

Founded in 2000, Lumenalta is committed to reinventing the digital consulting services model. With a focus on custom technology solutions, Lumenalta combines technical expertise with a client-first mindset to deliver impactful outcomes. Through its radical engagement approach, Lumenalta partners with businesses to achieve transformation at speed and scale, lighting the way to tomorrow’s tech.

Media Contact
Company Name: Lumenalta
Contact Person: Julie Woon, Director of Content Marketing & Strategy
Email: Send Email
Phone: 1 212-702-9054
Address:1345 Avenue of the Americas 2nd Floor
City: New York
State: NY 10105
Country: United States
Website: https://lumenalta.com/

Non-alcoholic Steatohepatitis (NASH) Treatment Market 2032: Clinical Trials, Medication, EMA, PDMA, FDA Approvals, Epidemiology, Therapies, Companies by DelveInsight

“Non-alcoholic Steatohepatitis (NASH) Treatment Market”
Nonalcoholic Steatohepatitis companies working in the market are Inventiva Pharma, Zydus Therapeutics, Novo Nordisk A/S, Eli Lilly and Company, Madrigal Pharmaceuticals, Terns, Inc., Intercept Pharmaceuticals, Enyo Pharma, 89bio, Inc., Akero Therapeutics, and others.

(Albany, USA) DelveInsight’s “Nonalcoholic Steatohepatitis (NASH) Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Nonalcoholic Steatohepatitis (NASH), historical and forecasted epidemiology as well as the Nonalcoholic Steatohepatitis (NASH) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Nonalcoholic Steatohepatitis (NASH) market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Nonalcoholic Steatohepatitis (NASH) market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Nonalcoholic Steatohepatitis (NASH) treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Nonalcoholic Steatohepatitis (NASH) market.

 

Request for a Free Sample Report @ Nonalcoholic Steatohepatitis Market Forecast

 

Key facts of the Nonalcoholic Steatohepatitis (NASH) Market Report are:

  • According to DelveInsight, Nonalcoholic Steatohepatitis (NASH) market size is expected to grow at a decent CAGR by 2032.
  • Leading Nonalcoholic Steatohepatitis companies working in the market are Madrigal Pharmaceuticals, Intercept Pharmaceuticals, Cirius Therapeutics, Novo Nordisk, Inventiva, Galmed Pharmaceuticals, AstraZeneca, Galectin Therapeutics, Viking Therapeutics, Eli Lilly and Company, Terns Pharmaceuticals, Sinew Pharma, 89bio, Inc., Eccogene, Novartis Pharmaceuticals, Poxel SA, AngioLab, Pfizer, Arrowhead Pharma, LG Chem, Redx Pharma, Lipocine, Inc., CytoDyn, Inc., Alnylam Pharmaceuticals, Inc., Chemomab Therapeutics, NuSirt Biopharma, HK inno. N, Aligos Therapeutics, Altimmune, Inc., Kowa Pharmaceutical, Ionis Pharmaceuticals, NorthSea Therapeutics, Rivus Pharmaceuticals, Hanmi Pharmaceutical, Hepagene Therapeutics, HighTide Biopharma, Akero Therapeutics, Merck Sharp & Dohme LLC, Cascade Pharmaceuticals, Hepion Pharmaceuticals, Chipscreen Biosciences, Boston Pharmaceuticals, Bristol-Myers Squibb, Sunshine Lake Pharma, GSK plc., Future Medicine, Gilead Sciences, ENYO Pharma, Histogen, and others.
  • Key Nonalcoholic Steatohepatitis (NASH) Therapies expected to launch in the market are TERN-101, SNP-610, LJN452 (tropifexor + licogliflozin), PXL065, ALS-L1023, PF-06865571 + PF-05221304, PF-06835919, PF-06865571, ORMD-0801, Norucholic acid, NNC0194-0499, MN-001, MK-3655, MET642, MET409, LPCN 1144, LIK066, Leronlimab, ALN-HSD, RXC007, LR19018, LR19131, CM101, Leu-Mit-Sil (NS-0200), IN-A010, Efruxifermin (EFX), Efinopegdutide, JKB-122, CS0159 (Linafexor), CRV431, Chiglitazar sodium, ARO-PNPLA3, ECC4703, BOS-580, HEC96719, GSK4532990, BIO89-100, Cotadutide solution, Firsocostat, EPY001a, Emricasan, BMS-986036, BIO89-100, BI 456906, BFKB8488A, AXA1125, ASC 41, GS-9674 (Cilofexor), ZSP1601, and others.
  • In March 2023, Aligos Therapeutics presented Phase 1 data for its thyroid receptor-beta (THR-ß) agonist candidate, ALG-055009, at the 15th Paris Hepatology Conference, taking place virtually March 27 – 29, 2023.

 

Nonalcoholic Steatohepatitis (NASH) Overview

Nonalcoholic steatohepatitis (NASH) is a type of liver inflammation and damage caused by fat accumulation. It is one of the numerous disorders known as nonalcoholic fatty liver disease. Nonalcoholic fatty liver disease is divided into two types: isolated fatty liver, in which only fat accumulates, and nonalcoholic steatohepatitis, in which fat, inflammation, and liver cell damage accumulate. NASH does not usually cause symptoms. Most people with NASH feel fine and are unaware that they have it. As NASH progresses and liver damage worsens, a patient may experience fatigue, weight loss, general weakness, and acne in the upper right part of the belly. Screening for nonalcoholic fatty liver disease in the general population is not advised. It is usually considered after discovering unexplained liver enzyme levels or imaging reveals hepatic steatosis. A patient’s medical history, a physical exam, and tests for nonalcoholic steatohepatitis are used by doctors.

 

Learn more about NASH treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Nonalcoholic Steatohepatitis Treatment Market

 

Nonalcoholic Steatohepatitis (NASH) Market 

The Nonalcoholic Steatohepatitis (NASH) market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Nonalcoholic Steatohepatitis (NASH) market trends by analyzing the impact of current Nonalcoholic Steatohepatitis (NASH) therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Nonalcoholic Steatohepatitis (NASH) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Nonalcoholic Steatohepatitis (NASH) market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Nonalcoholic Steatohepatitis (NASH) market in 7MM is expected to witness a major change in the study period 2019-2032.

 

Nonalcoholic Steatohepatitis (NASH) Epidemiology 

The Nonalcoholic Steatohepatitis (NASH) epidemiology section provides insights into the historical and current Nonalcoholic Steatohepatitis (NASH) patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Nonalcoholic Steatohepatitis (NASH) market report also provides the diagnosed patient pool, trends, and assumptions. 

 

Explore more about Nonalcoholic Steatohepatitis (NASH) Epidemiology @ Nonalcoholic Steatohepatitis (NASH) Prevalence

 

Nonalcoholic Steatohepatitis (NASH) Drugs Uptake

This section focuses on the uptake rate of the potential Nonalcoholic Steatohepatitis (NASH) drugs recently launched in the Nonalcoholic Steatohepatitis (NASH) market or expected to be launched in 2019-2032. The analysis covers the Nonalcoholic Steatohepatitis (NASH) market uptake by drugs, patient uptake by therapies, and sales of each drug.   

Nonalcoholic Steatohepatitis (NASH) Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Nonalcoholic Steatohepatitis (NASH) market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

 

Nonalcoholic Steatohepatitis (NASH) Pipeline Development Activities

The Nonalcoholic Steatohepatitis (NASH) report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Nonalcoholic Steatohepatitis (NASH) key players involved in developing targeted therapeutics.

 

 

Request for a sample report to understand more about the Nonalcoholic Steatohepatitis (NASH) pipeline development activities @ Nonalcoholic Steatohepatitis (NASH) Therapies and Drugs

 

Nonalcoholic Steatohepatitis (NASH) Therapeutics Assessment

Major key companies are working proactively in the Nonalcoholic Steatohepatitis (NASH) Therapeutics market to develop novel therapies which will drive the Nonalcoholic Steatohepatitis (NASH) treatment markets in the upcoming years are Madrigal Pharmaceuticals, Intercept Pharmaceuticals, Cirius Therapeutics, Novo Nordisk, Inventiva, Galmed Pharmaceuticals, AstraZeneca, Galectin Therapeutics, Viking Therapeutics, Eli Lilly and Company, Terns Pharmaceuticals, Sinew Pharma, 89bio, Inc., Eccogene, Novartis Pharmaceuticals, Poxel SA, AngioLab, Pfizer, Arrowhead Pharma, LG Chem, Redx Pharma, Lipocine, Inc., CytoDyn, Inc., Alnylam Pharmaceuticals, Inc., Chemomab Therapeutics, NuSirt Biopharma, HK inno. N, Aligos Therapeutics, Altimmune, Inc., Kowa Pharmaceutical, Ionis Pharmaceuticals, NorthSea Therapeutics, Rivus Pharmaceuticals, Hanmi Pharmaceutical, Hepagene Therapeutics, HighTide Biopharma, Akero Therapeutics, Merck Sharp & Dohme LLC, Cascade Pharmaceuticals, Hepion Pharmaceuticals, Chipscreen Biosciences, Boston Pharmaceuticals, Bristol-Myers Squibb, Sunshine Lake Pharma, GSK plc., Future Medicine, Gilead Sciences, ENYO Pharma, Histogen, and others.

 

Request for NASH Market Dynamics @ NASH Clinical Trials and FDA Approval

 

Nonalcoholic Steatohepatitis (NASH) Report Key Insights

1. Nonalcoholic Steatohepatitis (NASH) Patient Population

2. Nonalcoholic Steatohepatitis (NASH) Market Size and Trends

3. Key Cross Competition in the Nonalcoholic Steatohepatitis (NASH) Market

4. Nonalcoholic Steatohepatitis (NASH) Market Dynamics (Key Drivers and Barriers)

5. Nonalcoholic Steatohepatitis (NASH) Market Opportunities

6. Nonalcoholic Steatohepatitis (NASH) Therapeutic Approaches

7. Nonalcoholic Steatohepatitis (NASH) Pipeline Analysis

8. Nonalcoholic Steatohepatitis (NASH) Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Nonalcoholic Steatohepatitis (NASH) Market

 

Table of Contents

1. Key Insights

2. Executive Summary

3. Nonalcoholic Steatohepatitis (NASH) Competitive Intelligence Analysis

4. Nonalcoholic Steatohepatitis (NASH) Market Overview at a Glance

5. Nonalcoholic Steatohepatitis (NASH) Disease Background and Overview

6. Nonalcoholic Steatohepatitis (NASH) Patient Journey

7. Nonalcoholic Steatohepatitis (NASH) Epidemiology and Patient Population

8. Nonalcoholic Steatohepatitis (NASH) Treatment Algorithm, Current Treatment, and Medical Practices

9. Nonalcoholic Steatohepatitis (NASH) Unmet Needs

10. Key Endpoints of Nonalcoholic Steatohepatitis (NASH) Treatment

11. Nonalcoholic Steatohepatitis (NASH) Marketed Products

12. Nonalcoholic Steatohepatitis (NASH) Emerging Therapies

13. Nonalcoholic Steatohepatitis (NASH) Seven Major Market Analysis

14. Attribute Analysis

15. Nonalcoholic Steatohepatitis (NASH) Market Outlook (7 major markets)

16. Nonalcoholic Steatohepatitis (NASH) Access and Reimbursement Overview

17. KOL Views on the Nonalcoholic Steatohepatitis (NASH) Market

18. Nonalcoholic Steatohepatitis (NASH) Market Drivers

19. Nonalcoholic Steatohepatitis (NASH) Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

 

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/case-study/cdmo-competitive-assessment

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Non-alcoholic Steatohepatitis (NASH) Treatment Market 2032: Clinical Trials, Medication, EMA, PDMA, FDA Approvals, Epidemiology, Therapies, Companies by DelveInsight